Shield Therapeutics (FRA:1JS) Other Gross PPE: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Shield Therapeutics Other Gross PPE?

Shield Therapeutics FRA:1JS +1.20% Other Gross PPE is €0.00 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Shield Therapeutics's Other Gross PPE for the quarter that ended in Dec. 2025 was €0.00 Mil.

Shield Therapeutics's quarterly Other Gross PPE declined from Dec. 2024 (€0.69 Mil) to Jun. 2025 (€0.20 Mil) and declined from Jun. 2025 (€0.20 Mil) to Dec. 2025 (€0.00 Mil).

Shield Therapeutics's annual Other Gross PPE increased from Dec. 2023 (€0.66 Mil) to Dec. 2024 (€0.69 Mil) but then declined from Dec. 2024 (€0.69 Mil) to Dec. 2025 (€0.00 Mil).

Shield Therapeutics Other Gross PPE Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Other Gross PPE Chart

Shield Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.29 0.66 0.69 0.00

Shield Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.49 0.69 0.20 0.00

Shield Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Frequently Asked Questions Learn more about Other Gross PPE →
What does a Other Gross PPE of €0.00 Mil mean?
Shield Therapeutics (FRA:1JS) has a Other Gross PPE of €0.00 Mil as of Dec. 2025. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Shield Therapeutics and its competitors.
Is Shield Therapeutics' Other Gross PPE too high?
Shield Therapeutics' current Other Gross PPE is €0.00 Mil.
How does Shield Therapeutics' Other Gross PPE compare to ZTS and UTHR?
Shield Therapeutics' Other Gross PPE of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Gross PPE for a Drug Manufacturers company?
A good Other Gross PPE depends on the Drug Manufacturers industry context. However, Other Gross PPE should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Gross PPE mean?
A high Other Gross PPE can signal that a stock is expensive relative to its fundamentals. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Shield Therapeutics and its competitors. Shield Therapeutics's current Other Gross PPE is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (FRA:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.04 — trading 58% below its estimated fair value. The current Other Gross PPE is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Gross PPE calculated?
Other Gross PPE is calculated from a company's financial statements. For Shield Therapeutics (FRA:1JS), the current Other Gross PPE is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.